Search results
Results from the WOW.Com Content Network
4F-MDMB-BINACA (also known as MDMB-4F-BINACA, [2] 4F-MDMB-BUTINACA or 4F-ADB) is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family. [3] It should not be confused with the amantadine analogue 4F-ABINACA. It has been used as an active ingredient in synthetic cannabis products and sold as a designer drug since late 2018.
Researchers have pointed out a few ways that synthetic cannabinoids differ from marijuana, and therefore may be more dangerous. First, they often have greater intrinsic activity. Many of the synthetic cannabinoids are full agonists of the cannabinoids receptors, CB 1 and CB 2, compared to THC, which is only a partial agonist. [66]
S-444,823 is a drug developed by Shionogi which is a cannabinoid agonist. [1] It was developed as an antipruritic, and has moderate selectivity for the CB 2 subtype, having a CB 2 affinity of 18nM, and 32x selectivity over the CB 1 receptor.
AM-679 was one of the first 3-(2-iodobenzoyl)indole derivatives that was found to have significant cannabinoid receptor affinity, and while AM-679 itself has only modest affinity for these receptors, it was subsequently used as a base to develop several more specialised cannabinoid ligands that are now widely used in research, including the ...
Urine contained 2.1 μg/L for the metabolite, and a detection below level of quantification for MDMB-4en-PINACA itself. [ 23 ] Adulterated Cannabis products in Europe that have been laced with MDMB-4en-PINACA have contained 0.3 to 4.6 μg/mg in seized flower samples and 1.7 to 7.2 μg/mg in hash/or other extract samples.
Pages for logged out editors learn more. ... Download as PDF; Printable version ... pyridine-3-carboxamide based synthetic cannabinoid that has been sold as a ...
O-1602 is a synthetic compound most closely related to abnormal cannabidiol, and more distantly related in structure to cannabinoid drugs such as THC.O-1602 does not bind to the classical cannabinoid receptors CB 1 or CB 2 with any significant affinity, but instead is an agonist at several other receptors which appear to be related to the cannabinoid receptors, particularly GPR18 and GPR55.
AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole) is a recreational designer drug that acts as a potent but nonselective full agonist for the cannabinoid receptor. [3] It is part of the AM series of cannabinoids discovered by Alexandros Makriyannis at Northeastern University .